Transforming growth factor-β signaling promotes pulmonary hypertension caused by schistosoma mansoni

Circulation

Volumn 128, Issue 12, 2013, Pages 1354-1364

  Graham, Brian B ^a,c   Chabon, Jacob ^a   Gebreab, Liya ^a   Poole, Jennifer ^a   Debella, Elias ^a   Davis, Laura ^a   Tanaka, Takeshi ^a   Sanders, Linda ^a   Dropcho, Nina ^a   Bandeira, Angela ^a,c,d   Vandivier, R William ^a   Champion, Hunter C ^a,c,e   Butrous, Ghazwan ^a,c,f   Wang, Xiao Jing ^b   Wynn, Thomas A ^g   Tuder, Rubin M ^a,c  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Pathology ^*  (United States)

^c Pulmonary Vascular Research Institute   (United States)

^d FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF KENT   (United Kingdom)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

hypertension, pulmonary; schistosomiasis; transforming growth factor beta

Indexed keywords

INTERLEUKIN 13; INTERLEUKIN 4; RHO KINASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; LUNG ARTERY PRESSURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; SCHISTOSOMIASIS MANSONI; SENSITIZATION; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; TH2 CELL; VASOCONSTRICTION;

HYPERTENSION, PULMONARY; SCHISTOSOMIASIS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; MICE; MICE, 129 STRAIN; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED ICR; MICE, TRANSGENIC; PULMONARY CIRCULATION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; VASOCONSTRICTION;

EID: 84884279892     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003072     Document Type: Article

References (27)

1. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation. 2008;118:1758-1766.
2. Ward TJC, Fenwick A, Butrous G. The prevalence of pulmonary hypertension in schistosomiasis: a systematic review. PVRI Review. 2011;3:12-21.
3. Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM. Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. Chest. 2010;137(suppl):20S-29S.
4. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med. 2009;30:376-385.
5. Boros DL, Whitfield JR. Enhanced Th1 and dampened Th2 responses synergize to inhibit acute granulomatous and fibrotic responses in murine schistosomiasis mansoni. Infect Immun. 1999;67:1187-1193.
6. de Jesus AR, Silva A, Santana LB, Magalhães A, de Jesus AA, de Almeida RP, Rêgo MA, Burattini MN, Pearce EJ, Carvalho EM. Clinical and immunologic evaluation of 31 patients with acute schistosomiasis mansoni. J Infect Dis. 2002;185:98-105.
7. Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 2009;31: 163-176.
8. Kaviratne M, Hesse M, Leusink M, Cheever AW, Davies SJ, McKerrow JH, Wakefield LM, Letterio JJ, Wynn TA. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol. 2004;173:4020-4029.
9. Graham BB, Mentink-Kane MM, El-Haddad H, Purnell S, Zhang L, Zaiman A, Redente EF, Riches DW, Hassoun PM, Bandeira A, Champion HC, Butrous G, Wynn TA, Tuder RM. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol. 2010;177:1549-1561.
10. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science. 2011;332:1284-1288.
11. Montani D, Perros F, Gambaryan N, Girerd B, Dorfmuller P, Price LC, Huertas A, Hammad H, Lambrecht B, Simonneau G, Launay JM, Cohen-Kaminsky S, Humbert M. C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;184:116-123.
12. Varghese AJ, Gulyas S, Mohindra JK. Hypoxia-dependent reduction of 1-(2-nitro-1-imidazolyl)-3-methoxy-2-propanol by Chinese hamster ovary cells and KHT tumor cells in vitro and in vivo. Cancer Res. 1976;36:3761-3765.
13. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med. 2008;205:361-372.
14. Nomura M, Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature. 1998;393:786-790.
15. Richter A, Yeager ME, Zaiman A, Cool CD, Voelkel NF, Tuder RM. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1340-1348.
16. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81-84.
17. Crosby A, Soon E, Jones F, Southwood M, Dunmore B, Dunne D, Morrell NW. Bmpr-ii deficiency does not worsen pulmonary arterial hypertension in the mouse model of chronic schistosomiasis infection. Am J Respir Crit Care Med. 2012;185:A3438.
18. Ma W, Han W, Greer PA, Tuder RM, Toque HA, Wang KK, Caldwell RW, Su Y. Calpain mediates pulmonary vascular remodeling in rodent models of pulmonary hypertension, and its inhibition attenuates pathologic features of disease. J Clin Invest. 2011;121:4548-4566.
19. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, Shimoda LA, Neptune E, Higgins L, Murphy A, Chakravarty S, Protter A, Sehgal PB, Champion HC, Tuder RM. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:896-905.
20. Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
21. Nagaoka T, Morio Y, Casanova N, Bauer N, Gebb S, McMurtry I, Oka M. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol. 2004;287:L665-L672.
22. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res. 2007;100:923-929.
23. Japyassú FA, Mendes AA, Bandeira ÂP, Oliveira FR, Sobral Filho D. Hemodynamic profile of severity at pulmonary vasoreactivity test in schistosomiasis patients. Arq Bras Cardiol. 2012;99:789-796.
24. Hoot KE, Lighthall J, Han G, Lu SL, Li A, Ju W, Kulesz-Martin M, Bottinger E, Wang XJ. Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest. 2008;118:2722-2732.
25. Shadan S. Drug discovery: schistosome treatment. Nature. 2008;452:296.
26. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis. 2006;6:411-425.
27. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev. 2010;19:46-54.